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MESTThe long term use of antiepileptic drugs possesses many unwanted effects; thus, new safe com-
binations are urgently mandated. Hence, the present study aimed to investigate the anticonvul-
sant effect of kava alone or in combination with a synthetic anticonvulsant drug, diazepam
(DZ). To this end, female Wistar rats were divided into two subsets, each comprising 6 groups
as follows: group (i) received 1% Tween 80 p.o. and served as control, while groups (ii) and (iii)
received kava at two dose levels (100 and 200 mg/kg, p.o.). The remaining three groups received
(iv) DZ alone (10 mg/kg p.o.) or kava in combination with DZ (v) (5 mg/kg, p.o.) or (vi) (10 mg/
kg, p.o.). Results of the present study revealed that kava increased the maximal electroshock
seizure threshold (MEST) and enhanced the anticonvulsant effect of diazepam following both
acute and chronic treatment. Moreover, neither kava nor its combination with DZ impaired
motor co-ordination either acutely or chronically. Furthermore, kava ameliorated both the
reduction in locomotor activity as well as changes in liver function tests induced by chronic
administration of DZ. Moreover, no elevation was shown in the creatinine concentration vs.
control group following chronic administration of kava or DZ either alone or in combination
with kava. In conclusion, the present study suggests the possibility of combining a low dose
588 R.A. Tawﬁq et al.DZ with kava to reduce harmful effects and might be recommended for clinical use in patients
chronically treated with this synthetic anticonvulsant drug.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
Conventionally, treatment of epilepsy is symptomatic using
available synthetic antiepileptic drugs (AEDs) [1]. However,
the incidence of a plethora of side effects with orthodox AEDs
possesses major compliance limitations to epileptic therapies
[2]. Many herbal sedatives, viz kava were thought to enhance
the effects of antiepileptic drugs [3]. Kava extract (Piper
methysticum), that is popularly used as an over the counter
(OTC) anxiolytic drug, retains anticonvulsant action without
impairing alertness or cognitive functioning [4]. Kavalactones,
which constitute the major active components of kava extract,
are thought to possess anticonvulsant efﬁcacy [3,5].
A report by Gomes et al. [5] provided compelling evidence
for the alternative use of kava in lieu of benzodiazepines
(BDZs) in treating mild anxiety. Indeed, BDZs present an
important class in treatment of epilepsy [6]; however, the inci-
dence of side effects with the use of this class limits their utility
[7]. Hence, it became the objective of the current investigation
to study the effect of using either kava alone or its combination
with diazepam (DZ), a BDZ compound, in an animal model of
epilepsy. Moreover, the study investigated the reduction in
incidence of side effects induced by DZ, thus providing evi-
dence for the safe use in combination with kava.
Material and methods
Animals
Adult female Wistar rats, weighing 120–200 g (6–9 weeks) [8],
obtained from the animal house of the National Research Cen-
ter (Dokki, Giza, Egypt) were kept at a constant humidity
(60 ± 10%), temperature (23 ± 2 C) and a light/dark (12 h)
cycle. Animals were allowed standard laboratory chow (20%
proteins, 5% fats, and 1% multivitamins) and water ad lib.
Animal care and experimental protocol complied with the Guide
for the Care and Use of Laboratory Animals published by the
US National Institutes of Health (NIH Publication No. 85-23,
revised 1996) and was approved by Research Ethical Committee
of Faculty of Pharmacy Cairo University (Cairo, Egypt). All
experiments were performed during the light phase of the
light/dark cycle after at least a 60 min period of acclimatization
to the experimental room. Female rats were used owing to their
ability to eliminate drugs less rapidly than males [9]. Worthy of
note, testing, and chronic treatments were performed at
random times during the estrus cycle to minimize the effects
of any cyclic changes in endogenous neurosteroids [10].
Experimental design
Animals were divided into 2major sets; each subset comprised 6
groups (n= 8–10; each). The ﬁrst subset of groups was utilized
for testing behavioral (locomotor activity and muscle co-ordi-
nation), while the other subset was used for the anticonvulsant
effect by inducing electroconvulsive shock. However,biochemical assays were carried out on both subsets. Rats were
allocated in the following groups (i) received 1% Tween 80 p.o.
and served as control group, while groups (ii) and (iii) received
lyophilized aqueous extract of kava (Atos Pharma, Sharqeya,
Egypt) at two dose levels. The ﬁrst dose (100 mg/kg, p.o.) was
utilized according to previous work by Bilia et al. [11], while
the second dose regimen (200 mg/kg, p.o.) was based on a pre-
vious pilot study. The remaining three groups received (iv) (DZ)
alone (El-Nile Co. for Pharmaceutical and Chemical Industries,
Cairo, Egypt) at a dose of (10 mg/kg) [12] or kava in combina-
tion with DZ (v) (5 mg/kg, p.o.) or (vi) (10 mg/kg, p.o.). Treat-
ments were carried out either acutely (1 h prior to testing) or on
chronic basis (once daily for seven consecutive days) [13].
Induction of electroconvulsive shock by electroconvulsive
treatment device (ECT)
The anticonvulsant effect was evaluated by using electrocon-
vulsive treatment for small mammals (ECT Unit, Ugo Basil,
57,800, Comerio, Italy). Brieﬂy, rats were subjected to ascend-
ing alternating electric current via the ear electrodes of the
ECT unit. Electric shock of duration 0.2 s, frequency
50 pulse/s and with pulse width 0.5 ms was generated by
ECT unit starting from 1 mA till the end point (occurrence
of tonic convulsions evidenced by hind limb extension) [14].
Locomotor activity test
The locomotor activity of rats was assessed using microproces-
sor controlled activity cage (Ugo-Basile, Model No. 7430,
Comerio, Italy). Before each exposure, animals were acclima-
tized for 1 h to the test room. Locomotor activity was mea-
sured as the total number of horizontal and vertical activity
of each rat. This measurement is deﬁned as the number of
beam interruptions throughout a 5-min observation period
[15]. Each drug was injected p.o. 60 min prior to locomotor
activity testing [16].
Motor co-ordination assay
The motor co-ordination or performance was investigated
using accelerating rotarod (Ugo-Basile, Model No. 7750,
Comerio, Italy, acceleration: 4–40 rpm in 5 min). The time be-
tween placing the subject on the rotating drum and that of its
falling-off was recorded as the retention time. Twenty-four
hours prior to the test execution, rats were subjected to 3–5
training sessions separated by at least 30 min in order to main-
tain their equilibrium on the test apparatus. A maximum of
300 s period was allowed for the animals to stay on the rod,
with an accelerating velocity starting from 4 rpm and acceler-
ated linearly to 40 rpm at the end of the session (5 min long)
[17]. Only rats that succeeded to maintain their equilibrium
on the rotarod for more than 120 s were selected for drug test-
ing [13]. This selection step at the beginning was to ensure that
all rats showed normal motor co-ordination.
Kava and epilepsy 589Biochemical tests
Animals used for biochemical analysis were euthanized and
blood samples were collected and centrifuged at 4000 rpm (ep-
pendorff, Hamburg, Germany) for 10 min to obtain clear sera.
Aspartate transaminase (AST; Quimica Clinica Aplicada S.A.,
Spain) [18]; ALT alanine transaminase (ALT; Quimica Clinica
Aplicada S.A., Spain) [18]; alkaline phosphatase (ALP; biodi-
agnostics, Giza, Egypt) activities [19] and creatinine concentra-
tion (Stanbio laboratory, Boerne, TX) [20] were assessed
according to the manufacturer’s instructions.
Statistical analysis
Data are expressed as mean of 8 experiments ± S.E.M., and
statistical comparisons were carried out using one way analysis
of variance (ANOVA) followed by Tukey Kramer Multiple
Comparisons Test. All analyses utilized were performed using
GraphPad Prism version 5. The minimal level of signiﬁcance
was identiﬁed at P< 0.05.
Results
Effect of kava, diazepam, or combination of kava with diazepam
acutely and chronically on maximal electroconvulsive shock
Following acute treatment with kava (100 mg/kg), the seizure
threshold was prolonged by 42% of control group. On the
other hand, kava (200 mg/kg) prolonged seizure threshold by
83% from control, hence showing signiﬁcant protection versusFig. 1 Effect of kava alone (top panels) or in combinations with
administration. Values are means (n= 8–10, each group) ± S.E.M. \,
or Kava(100 mg/kg)+DZ (5 mg/kg) respectively at P< 0.05. Statistica
Turkey–Kramer Multiple Comparison Test.the lower dose. Chronically, kava (100 mg/kg) showed signiﬁ-
cant seizure threshold prolongation, by 48% from control
group while kava (200 mg/kg) prolonged the seizure onset by
58% (Fig. 1a and b).
Following both acute and chronic DZ (10 mg/kg), seizure
threshold was prolonged by 115% and 52% from control,
respectively. Nevertheless, adding kava (100 mg/kg) to DZ
(10 mg/kg) showed surprising increment in the seizure thresh-
old, by 3 and 2 folds following both acute and chronic treat-
ment, respectively. These results were signiﬁcant from DZ
(10 mg/kg) alone. By the same token, adding kava (100 mg/
kg) to DZ (5 mg/kg), a signiﬁcant increase in seizure threshold
was observed by 2 folds and 108% from control values follow-
ing both acute and chronic treatment, respectively (Fig. 1c and
d).
Locomotor activity of kava, diazepam, or diazepam combination
with kava
Following acute and chronic treatment with kava (100;
200 mg/kg, p.o.), there was no change in the locomotor activity
vs. control (Fig. 2a and b). Conversely, acute and chronic
treatment with either DZ (10 mg/kg) alone or in combination
with kava reduced the locomotor activity of rats signiﬁcantly
vs control value (Fig. 2c and d).
However, on combining kava (100 mg/kg) with DZ (5 mg/
kg), rats showed no signiﬁcant difference vs. control either
acutely or chronically, i.e., the noticeable reduction in locomo-
tor activity occurred with DZ individual treatment disap-
peared; moreover, locomotor activity became signiﬁcantly
higher than that of DZ alone (Fig. 2c and d).DZ (lower panels) under acute (a and c) or chronic (b and d)
@, #, d different from control, Kava (100 mg/kg), DZ (10 mg/kg),
l comparisons were carried out using on way ANOVA followed by
Fig. 2 Effect of kava alone (top panels) or in combinations with DZ (lower panels) under acute (a and c) or chronic (b and d)
administration. Values are means (n= 8–10, each group) ± S.E.M. \, @, #, d different from control, Kava (100 mg/kg), DZ (10 mg/kg),
or Kava(100 mg/kg)+DZ (5 mg/kg) respectively at P< 0.05. Statistical comparisons were carried out using one-way ANOVA followed
by Turkey–Kramer Multiple Comparison Test.
Fig. 3 Effect of kava alone (top panels) or in combinations with DZ (lower panels) under acute (a and c) or chronic (b and d)
administration. Values are means (n= 8–10, each group) ± S.E.M. P< 0.05. Statistical comparisons were carried out using one-way
ANOVA followed by Turkey–Kramer Multiple Comparison Test.
590 R.A. Tawﬁq et al.Motor co-ordination after treatment with the tested drugs
In the current study, neither kava nor DZ altered the mo-
tor co-ordination of rats either after acute or after chronictreatment. Moreover, on adding kava to DZ at the two
dose levels, 5 or 10 mg/kg, the motor co-ordination of rats
did not change following the acute or chronic treatment
(Fig. 3).
Table 1 Liver function tests following kava chronic treatment at two dose levels.
Groups AST activity (U/ml) ALT activity (U/ml) ALP activity (IU/L)
Control 42.4 ± 6.1 31.8 ± 3.9 149 ± 14.8
Kava
100 mg/kg 51.8 ± 4.2 40.4 ± 5.3 174 ± 21.1
200 mg/kg 33.8 ± 1.7 38.7 ± 6.6 146 ± 13.5
Each value represents the mean (8–10 rats) ± S.E.M. Statistical comparisons (P< 0.05) were carried out using one-way ANOVA followed by
Turkey–Kramer Multiple Comparison Test.
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kava, DZ or their combination
Following chronic treatment with kava (100; 200 mg/kg, p.o.),
there was no change in AST, ALT, and ALP vs. control
(Table 1). Chronic treatment with DZ (10 mg/kg) alone or
its combination with kava (100 mg/kg, p.o.) caused signiﬁcant
increase in the ALT activity from control value. Conversely,
the combination of kava (100 mg/kg, p.o.) with DZ (5 mg/
kg, p.o.) showed signiﬁcant decrease in the ALT activity vs.
DZ but not control (Fig. 4b). Meanwhile, chronic DZ
(10 mg/kg) caused signiﬁcant reduction in the ALP activity
(Fig. 4c). However, the combination of kava (100 mg/kg) with
DZ (5; 10 mg/kg) induced no change in ALP activity.
Serum creatinine level following chronic treatment with kava,
DZ, or combination of kava with DZ at two dose levels
On chronic treatment with either kava (100; 200 mg/kg, p.o.) or
DZ (10 mg/kg), no alteration in serum creatinine level vs. con-
trol was elicited (Table 2). Paradoxically, chronic combinations
of kava (100 mg/kg, p.o.) with DZ (5; 10 mg/kg, p.o.) decreased
serum creatinine level from control value (Table 2). Moreover,
kava (100 mg/kg, p.o.), DZ (10 mg/kg, p.o.), and combinations
of kava (100 mg/kg, p.o.) with DZ (5; 10 mg/kg, p.o.) did not
alter the ratio of kidney weight/body weight (Table 2).
Discussion
Antiepileptic therapy with limited side effects remains unat-
tainable for many patients. The present study highlights the
following major ﬁndings (i) kava, a drug of natural origin, in-
creased the maximal electroconvulsive shock threshold
(MEST), thus offering an anticonvulsive potential in rats. This
protection was evident with both acute and chronic kava
administration; (ii) combination of kava with diazepam (DZ)
improved the protective effect of the latter on MEST; (iii) kava
alone at the indicated dose levels did not alter normal locomo-
tor activity nor motor co-ordination; in addition, (iv) kava in
combination with DZ did not cause any change in motor co-
ordination; (v) combining kava with DZ ameliorates the reduc-
tion in locomotor activity induced by chronic administration
of DZ; (vi) safety of kava on both liver and kidney functions.
Kava, at both tested doses, (100; 200 mg/kg, p.o.), showed
signiﬁcant increase in the MEST compared to control group
(1% Tween 80). These ﬁndings provide experimental evidence
for an anticonvulsant effect either for acute or chronic admin-
istration (Fig. 1a and b), which is in line with ﬁndings by Bilia
et al. [11]. The exact mechanism responsible for kava’s action isstill undeﬁned [5]; however, evidence supports that enhanced
ligand binding to c-aminobutyric acid (GABA) type A recep-
tors plays a marked role in mediating the anticonvulsant ef-
fects of kava [4]. Jussoﬁe et al. [21] studied kava extract
using GABAA receptor agonist (muscimol), which showed
enhancement of the binding to GABAA receptor in a concen-
tration-dependent manner. This effect was independent of
binding of kavalactones to GABAA and benzodiazepines
receptors [11]. However, other mechanisms have been pro-
posed for the anticonvulsant effect of kava. These mechanisms
encompass blockade of voltage-gated sodium and calcium ion
channels, positive modulation of the early K+ outward
current, diminished excitatory neurotransmitter release conse-
quent to calcium ion channel blockade through a non-NMDA
antiglutamatergic action [4,11]. During acute exposure, kava
dose dependently modulated MEST (Fig. 1a). Although kava
at both dose levels modulated MEST (Fig. 1b), the (200 mg/
kg, p.o.) showed no signiﬁcant difference from the (100 mg/
kg, p.o.) following chronic treatment. A plausible explanation
for this observation resides in the fact that kavalactones lead to
rapid up-regulation of GABAA receptor in the hippocampus
and frontal cortex of rats which on chronic treatment
suppresses the direct agonist effect of kavalactones on these
receptors [21].
DZ acutely (10 mg/kg, p.o.) increased the seizure threshold
of rats signiﬁcantly from control (Fig. 1c) which is in line with
Meierkord et al. [22]. Diazepam, a benzodiazepine, acts as an
allosteric agonistic modulator of the post- and pre-synaptic
GABAA receptor chloride channel complex [11]. Although fol-
lowing acute DZ administration (10 mg/kg, p.o.), seizure
threshold increased by 115%; however, in chronic paradigm,
the threshold increased only by 52%, a ﬁnding that points to-
ward development of tolerance to DZ anticonvulsant action;
such observation corroborates previous reports [23–25].
In fact, subsensitivity to GABA action has been demon-
strated following chronic benzodiazepine treatment [7].
In the present study, the co-administration of kava
(100 mg/kg, p.o.) whether acutely or chronically with either
DZ (10 mg/kg, p.o.) or DZ (5 mg/kg, p.o.) improved their anti-
convulsant activity against electro-induced convulsions. Sur-
prisingly, co-administration of kava (100 mg/kg, p.o.) with
DZ (5 mg/kg, p.o.) elicited enhanced protection than DZ
(10 mg/kg) alone (Fig. 1c and d). Noteworthy, on acute or
chronic combination of kava (100 mg/kg, p.o.) with DZ
(5 mg; 10 mg /kg), the seizure threshold increased signiﬁcantly
vs. DZ (10 mg/kg, p.o.) alone. These results are suggestive for
enhancement effect of kava on diazepam after acute and
chronic administration.
Although Wafford [7] stated that kavalactones are centrally
acting skeletal muscle relaxants, the current study provided
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ter motor co-ordination activity whether acutely or chronically
(Fig. 3a and b). By the same token, the previous ﬁnding holds
true for DZ at the designated dose (Fig. 3c and d), which is in
line with a report by Felipe et al. [26]. It was also noted that
following acute and chronic combinations of kava with DZ,
no motor impairment was observed compared to control.
Moreover, kava at the two dose levels (100; 200 mg/kg,
p.o.) did not alter the locomotor activity vs. control group
following both acute and chronic treatment (Fig. 2a and b).
Nevertheless, Garrett et al. [27] provided evidence that kava
dose-dependently decreased locomotor activity; however, one
might argue that the discrepancy in the current ﬁnding and
the reported literature might be attributed to species differ-
ence. In addition, in a prolonged study, ataxia, lethargy, and
abnormal breathing were evident in female rats at 1 and
2.0 g/kg following 2 weeks of treatment with Kava [28]. Based
on the behavioral ﬁndings, one might deduce that kava may
exert its anticonvulsant action directly on the central nervous
system and not through sedation.
Noteworthy, DZ (10 mg/kg, p.o.) reduced locomotor activ-
ity in both acute [12,27] and chronic [29] exposures compared
to control counterparts (Fig. 2c and d). This diminution in
locomotor activity of rats following to DZ administration is
in line with ﬁndings by Himmel et al. [12]. By the same token,
the combination of kava and DZ (10 mg/kg) caused signiﬁcant
reduction in locomotor activity of rats following acute as well
as chronic treatment (Fig. 2c and d). A plausible explanation
for this phenomenon might be attributed to the ability of kavaFig. 4 Effect of chronic administration of kava in combination
with DZ on (a) AST, (b) ALT and (c) ALP activities. Values are
means (n= 8–10, each group) ± S.E.M. \, @, #, d different from
control, DZ (10 mg/kg), or Kava (100 mg/kg)+DZ (5 mg/kg)
respectively at P< 0.05. Statistical comparisons were carried out
using one-way ANOVA followed by Turkey–Kramer Multiple
Comparison Test.to enhance the binding of GABAA ligands to its receptor in a
concentration-dependent manner [21]. This notion is further
supported by the ﬁnding that combination of kava with DZ
(5 mg/kg) showed no diminution in locomotor activity. Fur-
thermore, Garrett et al. [27] stated that DZ caused decrease
in locomotor activity in a dose-dependent manner.
Since kava-containing products were reported to develop li-
ver failure requiring liver transplantation that occurred in
some patients, the Food and Drug Administration (FDA) is-
sued a consumer advisory in 2002 about the potential risk
associated with the use of these products [30]. However, the
data presented in Table 1 support the potential safety of kava
on liver enzymes activity where chronic kava administration
elicited no elevation of alanine transaminase (ALT), aspartate
transaminase (AST), and alkaline phosphatase (ALP) at the
two dose levels. Noteworthy, it was previously reported that
kava, at similar doses to those employed in the current study,
did not affect neither liver enzymes nor cytochrome-P450 iso-
forms [31]. By the same token, Singh and Devkota [32] demon-
strated that daily dose of 200 or 500 mg of kava did not alter
liver functions manifest as alkaline phosphatase, lactate dehy-
drogenase nor AST and ALT. Moreover, Noor (2010) showed
not only no change in liver functions but also showed signiﬁ-
cant reduction in AST and ALT, suggesting not only a lack
of toxicity but potentially a hepatoprotective effect of kava
[33]. However, one cannot rule out that different extraction
methods and the solvents employed in the preparation of
kava-containing products might be account for the reported
hepatotoxicity associated with kava. Nevertheless, in the cur-
rent study, the employed kava extract was the aqueous one,
which has been shown to exert hepatoprotection [34].
In the current study, chronic administration of DZ (10 mg/
kg) did not alter the activity of AST (Fig. 4a) but increased the
activity of ALT (Fig. 4b). However, adding kava (100 mg/kg,
p.o.) to DZ (10 mg/kg, p.o.) decreased the percent elevation
occurring with DZ (10 mg/kg, p.o.) alone. On the contrary,
this elevation disappeared completely following administration
of kava (100 mg/kg) with low dose of DZ (5 mg/kg. p.o.)
chronically. However, the activity of ALP on chronic treat-
ment with the combination of kava (100 mg/kg) with DZ (5
or 10 mg/kg) showed no signiﬁcant change in ALP activity
vs. control, although DZ individual treatment showed signiﬁ-
cant decrease vs. control. This may be explained in view of en-
zyme induction property of the combination, thus inducing
metabolism of DZ.
On testing serum creatinine as an indicator to kidney func-
tion, neither of the two doses tested for kava following chronic
administration caused any change in the creatinine level vs.
control (Table 2). Accordingly, the present study showed no
adverse effects of kava on liver and kidney function parame-
ters, the matter which is consistent with Noor [33]. Following
creatinine assaying, data showed no change in the creatinine
concentration of DZ (10 mg/kg, p.o.), after chronic adminis-
tration (Table 2). Only the combinations of DZ (5 and
10 mg/kg) with kava (100 mg/kg) decreased the creatinine
blood level signiﬁcantly vs. control group. This low creatinine
level may be due to decrease in muscle mass, but that is not the
case in the herein study since there was no signiﬁcant lose in
body weight (Fig. 5). That may be attributed to the metabolic
property of DZ that causes diazepam to increase renal clear-
ance of creatinine, hence decreasing its serum concentration
[35].
Fig. 5 Effect of chronic administration of kava in combination
with DZ on (a) body weight, (b) liver weight, and (c) liver weight/
body weight. Values are means (n= 8–10, each group) ± S.E.M.
Statistical comparisons were carried out using one-way ANOVA
followed by Turkey–Kramer Multiple Comparison Test.
Table 2 Effect of chronic treatment with kava on serum creatinine level and relative kidney weight following chronic treatments.
Groups Serum creatinine level (mg/dL) Relative kidney weight
Control 1.66 ± 0.12 0.0071 ± 0.0001
Kava 100 mg/kg 1.21 ± 0.08 0.0067 ± 0.0003
200 mg/kg 1.39 ± 0.05 0.0065 ± 0.0002
DZ 10 mg/kg 1.33 ± 0.06 0.0071 ± 0.0002
Kava (100 mg/kg) + DZ (5 mg/kg) 1.15 ± 0.1a 0.0071 ± 0.0005
DZ (10 mg/kg) 1.19 ± 0.07a 0.0072 ± 0.0002
Each value represents the mean (8–10 rats) ± S.E.M. Statistical comparisons (P< 0.05) were carried out using one-way ANOVA followed by
Tukey–Kramer Multiple Comparison Test.
a Vs control.
Kava and epilepsy 593Conclusions
Collectively, data presented in this study point toward the fea-
sibility of combining kava (100 mg/kg) together with a lower
dose DZ than conventional therapy to treat epilepsy, particu-
larly, chronically. This is evident by the ability of such a com-
bination to increase MEST threshold without affecting either
motor co-ordination or locomotor activity, i.e., conserving
normal lifestyle. Moreover, this combination protected against
incidence of liver or kidney functional changes that render this
combination a safe alternative for synthetic anticonvulsants
without loss of therapeutic efﬁcacy. It is recommended forfuture researchers to carry out histopathological investigation
on liver and kidney tissues to ensure the safety of the herein
combination on body organs. Moreover, it would be interest-
ing to further assess the mechanism behind the improving ef-
fect of kava in combination with DZ and the effect of kava
and its combination on brain mediators as well.
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